Achieve Life SciencesSTU:SP4P -3.60%32 Net Current Asset Value is €0.14 as of Mar. 2026, which is 100% below its 10-year median of 3.07. GuruFocus rates STU:SP4P with a GF Score™ of 32/100. The stock has 4 warning signs investors should review. Among 942 Biotechnology companies, Achieve Life Sciences ranks worse than 92.99% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Achieve Life Sciences's net current asset value per share for the quarter that ended in Mar. 2026 was €0.14.
The historical rank and industry rank for Achieve Life Sciences's Net Current Asset Value or its related term are showing as below:
STU:SP4P'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.66 Med: 3.07 Max: 53.75
Current: 38.21
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Achieve Life Sciences was 53.75. The lowest was 0.66. And the median was 3.07.
STU:SP4P's Price-to-Net-Current-Asset-Value is ranked worse than 92.99% of 942
companies
in the Biotechnology industry
Industry Median: 4.94
vs STU:SP4P: 38.21
Achieve Life Sciences (STU:SP4P) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Achieve Life Sciences Net Current Asset Value Related Terms
Achieve Life Sciences Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Achieve Life Sciences's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Achieve Life Sciences Net Current Asset Value Chart
STU:SP4P vs STTK, CRMD, EIKN: Net Current Asset Value Comparison
For the Biotechnology subindustry, Achieve Life Sciences's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Achieve Life Sciences Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Achieve Life Sciences's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Achieve Life Sciences's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of €0.14 mean?
Achieve Life Sciences (STU:SP4P) has a Net Current Asset Value of €0.14 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Achieve Life Sciences and its competitors. This is 95% below median its historical median of 3.07. Over the past decade, Achieve Life Sciences' Net Current Asset Value has ranged from 0.66 to 53.75. According to the industry distribution chart, Achieve Life Sciences ranks #876 out of 942 companies in the Biotechnology industry, placing it in the top 93%.
Is Achieve Life Sciences' Net Current Asset Value too high?
Achieve Life Sciences' current Net Current Asset Value of €0.14 is 95% below median its 10-year median of 3.07. Over the past 10 years, this metric has ranged from a low of 0.66 to a high of 53.75. Based on the distribution chart, Achieve Life Sciences ranks #876 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Achieve Life Sciences has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Achieve Life Sciences' Net Current Asset Value compare to STTK and CRMD?
According to the Biotechnology industry distribution chart, Achieve Life Sciences ranks #876 out of 942 companies for Net Current Asset Value. This places Achieve Life Sciences in the lower half of its industry. The industry median Net Current Asset Value is 4.94. Historically, Achieve Life Sciences' own Net Current Asset Value has ranged from 0.66 to 53.75 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.94, based on 942 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Achieve Life Sciences and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Achieve Life Sciences's current Net Current Asset Value is €0.14, which is 95% below median its own 10-year median of 3.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Achieve Life Sciences stock overvalued right now?
Achieve Life Sciences (STU:SP4P) has a current Net Current Asset Value of €0.14. The current Net Current Asset Value is €0.14, which is 95% below median its 10-year median of 3.07. Achieve Life Sciences' overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Achieve Life Sciences (STU:SP4P), the current Net Current Asset Value is €0.14 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.
32GF Score
Get the complete analysis for STU:SP4P
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:SP4P has been successfully added to your 
